Current research into semiconductor clusters is focused on the properties of quantum dots-fragments of semiconductor consisting of hundreds to many thousands of atoms-with the bulk bonding geometry and with surface states eliminated by enclosure in a material that has a larger band gap. Quantum dots exhibit strongly size-dependent optical and electrical properties. The ability to join the dots into complex assemblies creates many opportunities for scientific discovery.

Semiconductor Clusters, Nanocrystals, and Quantum Dots

Dye-sensitized solar cells (DSCs) offer the possibilities to design solar cells with a large flexibility in shape, color, and transparency. DSC research groups have been established around the worl ...

/pdf/dye-sensitized-solar-cells-50b0w2bhsr.pdf

Dye-Sensitized Solar Cells

Novel physical phenomena can emerge in low-dimensional nanomaterials. Bulk MoS2, a prototypical metal dichalcogenide, is an indirect bandgap semiconductor with negligible photoluminescence. When the MoS2 crystal is thinned to monolayer, however, a strong photoluminescence emerges, indicating an indirect to direct bandgap transition in this d-electron system. This observation shows that quantum confinement in layered d-electron materials like MoS2 provides new opportunities for engineering the electronic structure of matter at the nanoscale.

Emerging Photoluminescence in Monolayer MoS2

Bulk nanostructured materials from severe plastic deformation

Nanotechnology is a multidisciplinary field, which covers a vast and diverse array of devices derived from engineering, biology, physics and chemistry. These devices include nanovectors for the targeted delivery of anticancer drugs and imaging contrast agents. Nanowires and nanocantilever arrays are among the leading approaches under development for the early detection of precancerous and malignant lesions from biological fluids. These and other nanodevices can provide essential breakthroughs in the fight against cancer.

Cancer nanotechnology: opportunities and challenges.

The invention relates to the treatment of cancer. In particular the invention relates to an internal therapeutic product comprising: (i) an anti-cancer component selected from one or both of: a radionucleotide, a cytotoxic drug; and (ii) a silicon component selected from one or more of: resorbable silicon, biocompatible silicon, bioactive silicon, porous silicon, polycrystalline silicon, amorphous silicon, and bulk crystalline silicon, the internal therapeutic product being for the treatment of cancer.

Silicon implants comprising a radionucleotide and/or a cytotoxic drug and their use in cancer treatment

This chapter focuses on cell immunoisolation and bio-filtration applications of porous silicon membranes. After an introduction on immunoisolation for the treatment of diabetes, the different materials used for that function are reviewed and compared. Applications involving porous silicon are then presented in more detail. Other uses of microfabricated porous silicon membranes in hemofiltration and protein sorting are also discussed.

Porous silicon in immunoisolation and bio-filtration

L'invention comprend une composition comprenant une matiere de support a base de silicium poreuse bioerodable dans laquelle la matiere de support supporte au moins un agent therapeutique de grande molecule et au moins un sucre amorphe, comprenant en outre facultativement un inhibiteur de cristallisation. La composition peut etre utilisee in vitro ou in vivo pour administrer l'agent therapeutique, de preference d'une maniere controlee sur une periode etendue de temps telle que sur de multiples jours, semaines ou mois. La composition peut etre utilisee pour le traitement ou la prevention d'etats d'un patient tels que des maladies chroniques.

Compositions à base de silicium bioérodables pour l'administration d'agents thérapeutiques

This invention discloses reservoirs, such as implants for delivering therapeutic agents, particularly large molecules such as proteins and antibodies. The reservoirs may comprise a porous silicon-based carrier material impregnated with the therapeutic agent. The reservoir may be used in vitro or in vivo to maintain an equilibrium concentration of a therapeutic agent over an intended period of time such as over multiple days, weeks, months, or years. Additionally, the reservoir may be reloaded with additional therapeutic agent. These reservoirs may be used for treating or preventing conditions of a subject such as chronic diseases.

Compositions and Methods for Controlled Release of Agents

PROBLEM TO BE SOLVED: To provide silicone fibers and silicone fabrics for use as medical fibers and fabrics, these application, and methods for their production. SOLUTION: The fiber or fabric comprising silicone for use as the medical fiber or fabric. The silicon can be biocompatible, bioactive or resorbable material and may also be able to act as an electrical conductor. In addition, porous silicon may be used as a slow release means for example for drugs or fragrances, or as a collector for example for sweat. Novel fibers, fabrics and methods of preparation of these are also described and claimed. COPYRIGHT: (C)2009,JPO&INPIT

Leigh T. Canham

Papers

Silicon implants comprising a radionucleotide and/or a cytotoxic drug and their use in cancer treatment

Porous silicon in immunoisolation and bio-filtration

Compositions à base de silicium bioérodables pour l'administration d'agents thérapeutiques

Compositions and Methods for Controlled Release of Agents

Medical fiber and fabric